sinc
discoveri
middl
east
respiratori
syndrom
coronaviru
merscov
viru
caus
case
diseas
fatal
rate
diseas
initi
describ
patient
saudi
arabia
june
merscov
caus
sporad
case
cluster
famili
healthcar
set
best
treatment
option
viru
known
view
high
casefat
rate
potenti
global
spread
viru
urgent
need
develop
effect
therapi
infect
recent
review
base
therapi
use
relat
sever
acut
respiratori
syndrom
sar
coronaviru
possibl
use
interferon
ribavirin
consid
therapeut
option
purpos
studi
describ
outcom
use
combin
ribavirin
manag
five
patient
merscov
infect
woman
diabet
hypertens
endstag
renal
diseas
esrd
hemodialysi
admit
fever
cough
respiratori
failur
durat
tabl
test
posit
merscov
pcr
baselin
laboratori
data
shown
tabl
admiss
patient
start
oseltamivir
mg
daili
day
levofloxacin
mg
intraven
iv
everi
day
day
imipenem
ad
day
day
day
admiss
start
ribavirin
day
load
dose
mg
via
nasogastr
tube
follow
mg
per
os
po
everi
h
one
dose
mg
subcutan
methylprednisolon
mg
iv
everi
h
day
twice
daili
day
daili
day
mild
rise
amylas
lipas
ul
ul
respect
patient
remain
critic
ill
mechan
ventil
requir
inotrop
support
die
day
admiss
respiratori
multiorgan
failur
man
diabet
hypertens
esrd
hemodialysi
admit
cough
fever
hypoxem
respiratori
failur
durat
test
posit
merscov
pcr
baselin
laboratori
data
shown
tabl
admiss
patient
start
oseltamivir
mg
daili
day
levofloxacin
mg
iv
everi
day
day
imipenem
mg
iv
twice
daili
day
day
prescrib
methylprednisolon
mg
iv
everi
h
day
everi
h
day
mg
everi
h
day
follow
prednisolon
taper
dose
anoth
day
day
admiss
start
ribavirin
day
load
dose
mg
po
follow
mg
everi
h
two
dose
mg
subcutan
per
week
two
week
initi
therapi
platelet
drop
l
tabl
patient
remain
ventil
day
die
day
admiss
multiorgan
failur
woman
histori
sever
bronchial
asthma
obstruct
sleep
apnea
continu
posit
airway
pressur
cpap
coronari
arteri
diseas
diabet
hypertens
chronic
kidney
diseas
estim
glomerular
filtrat
rate
mlmin
admit
fever
cough
dyspnea
durat
diagnosi
pneumonia
test
posit
merscov
pcr
baselin
laboratori
data
shown
tabl
admiss
patient
also
start
oseltamivir
mg
daili
day
levofloxacin
mg
iv
everi
day
day
imipenem
mg
iv
everi
h
day
day
start
ribavirin
day
load
dose
mg
via
nasogastr
tube
follow
mg
po
everi
h
one
dose
mg
subcutan
prednison
mg
po
daili
taper
mg
po
daili
day
one
week
initi
antivir
steroid
therapi
serum
creatinin
aspart
aminotransferas
ast
tabl
amylas
increas
mgdl
l
iul
ul
respect
patient
diagnos
pancreat
thu
interferon
ribavirin
given
patient
remain
critic
ill
mechan
ventil
die
day
admiss
multiorgan
failur
man
histori
atrial
fibril
diabet
mellitu
hypertens
admit
progress
respiratori
distress
hypoxemia
fever
day
test
posit
merscov
pcr
baselin
laboratori
data
shown
tabl
first
day
hospit
patient
start
oseltamivir
mg
daili
day
levofloxacin
mg
everi
h
day
imipenem
mg
iv
everi
h
day
day
admiss
start
ribavirin
day
load
dose
mg
via
nasogastr
tube
follow
mg
via
nasogastr
tube
everi
h
two
dose
mg
subcutan
per
week
hospit
day
methylprednisolon
mg
iv
everi
h
day
mg
iv
twice
daili
day
mg
daili
day
start
hospit
day
three
week
initi
therapi
hemoglobin
drop
gdl
tabl
bilirubin
increas
mg
dl
suggest
hemolysi
patient
die
day
admiss
multiorgan
failur
man
histori
esrd
hemodialysi
admit
febril
ill
cough
day
respiratori
failur
requir
mechan
ventil
test
posit
merscov
pcr
baselin
laboratori
data
shown
tabl
first
day
hospit
patient
start
oseltamivir
mg
daili
day
imipenem
mg
iv
twice
daili
day
day
admiss
start
ribavirin
day
load
dose
mg
via
nasogastr
tube
follow
mg
via
nasogastr
tube
everi
h
two
dose
mg
subcutan
per
week
hospit
day
day
start
ribavirin
also
start
methylprednisolon
mg
iv
everi
h
day
mg
iv
twice
daili
day
mg
daili
day
two
week
initi
therapi
lipas
increas
ul
patient
die
day
admiss
multiorgan
failur
review
case
five
patient
merscov
tabl
median
age
rang
year
patient
chronic
kidney
diseas
four
mainten
hemodialysi
three
men
two
women
patient
test
neg
influenza
median
number
day
admiss
therapi
ribavirin
interferon
rang
tabl
patient
receiv
adjunct
corticosteroid
therapi
acut
respiratori
distress
syndrom
two
patient
develop
increas
lipas
initi
therapi
given
corticosteroid
time
antivir
therapi
one
patient
case
develop
thrombocytopenia
platelet
count
drop
l
tabl
one
patient
possibl
hemolysi
case
patient
sever
diseas
progress
respiratori
failur
develop
multiorgan
failur
die
mean
standard
deviat
day
admiss
none
patient
bacteremia
fungemia
hospit
stay
figur
show
median
minimum
maximum
valu
amylas
lipas
lactat
dehydrogenas
ldh
patient
initi
therapi
therapi
initi
sinc
emerg
merscov
viru
caus
total
case
diseas
high
casefat
rate
urgent
need
effect
therapeut
agent
date
data
avail
use
agent
therapi
merscovposit
patient
report
describ
therapi
five
merscov
patient
receiv
interferon
ribavirin
patient
treat
initi
phase
alhasa
outbreak
april
may
time
diseas
epidemiolog
clinic
characterist
known
henc
inevit
time
laps
admiss
initi
therapi
patient
alreadi
mechan
ventil
time
interferon
ribavirin
therapi
institut
fatal
outcom
patient
receiv
therapi
late
cours
diseas
median
rang
day
admiss
late
therapi
may
contribut
poor
outcom
addit
sever
diseas
multipl
comorbid
patient
time
initi
antivir
therapi
critic
treatment
viral
infect
treatment
sarscov
effect
oseltamivir
ribavirin
observ
agent
start
day
symptom
onset
earli
therapi
ribavirin
within
h
hospit
diagnosi
sar
shown
associ
better
outcom
although
number
patient
enrol
studi
small
treatment
influenza
oseltamivir
therapi
earli
diseas
result
reduc
mortal
start
later
day
onset
symptom
earli
vitro
studi
show
ribavirin
interferon
antimerscov
activ
vitro
activ
interferon
augment
concomit
use
ribavirin
rhesu
macaqu
model
merscov
infect
combin
ribavirin
therapi
effect
limit
diseas
result
mild
radiograph
evid
pneumonia
treatment
given
within
h
inocul
rhesu
macaqu
treat
anim
lower
level
system
local
proinflammatori
marker
fewer
viral
genom
copi
although
preclin
data
promis
report
illustr
real
world
issu
deal
novel
emerg
viral
infect
patient
diagnos
week
ill
time
five
mechan
ventil
multipl
comorbid
like
advers
affect
clinic
outcom
addit
serial
virolog
determin
merscov
level
airway
secret
shed
light
possibl
virolog
clearanc
virolog
failur
clinic
failur
therapi
small
seri
advers
effect
combin
ribavirin
interferon
therapi
observ
three
case
side
effect
note
two
patient
pancreat
enzym
elev
one
signific
hemolysi
find
complic
presenc
abnorm
laboratori
find
even
initi
combin
therapi
difficult
determin
side
effect
due
diseas
progress
due
therapeut
drug
urgent
need
largescal
clinic
trial
determin
safest
effect
regim
treatment
novel
highli
fatal
emerg
infect
ribavirin
interferon
may
show
promis
use
need
prompt
advers
effect
monitor
close
therapeut
approach
test
care
clinic
studi
